Event Information

In this Lexology-hosted webinar, two of our experts in life sciences transactions, partners Claire Smith and Ellen Lambrix, navigated some of the key issues in cell and gene licensing deals.

They considered the points from both a licensor’s and a licensee’s perspective – taking into account the complex IP landscape, the non-traditional routes to market for these therapies and the innovative payment models that are increasingly being agreed downstream with healthcare providers (owing to the high cost of treatments) – and the impact that these factors have on core licensing provisions, such as the licence grant and milestone and royalty payments.